Reinforcing endothelial TRAIL protects against cancer metastasis
TRAIL proteins function as gatekeepers for vascular barrier integrity and blocks entry of cancer cells to metastatic sites
March 23, 2023
Leuven, 23 March 2023 – Researchers from the lab of Prof. Max Mazzone (VIB-KU Leuven Center for Cancer Biology) have discovered that the family of TRAIL proteins in the endothelium plays a role in metastasis. Moreover, researchers demonstrated that counteracting TRAIL receptor DR5 in endothelial cells and promoting exogenous expression of TRAIL via mRNA technology can protect against breast cancer metastasis. The discovery is an important step toward the future development of new therapeutic approaches to prevent cancer metastasis.
Despite numerous successful advances in cancer treatment, specifically localized solid tumors, metastasis remains the Achilles heel of cancer therapy and the leading cause of death in cancer patients. The mechanisms behind metastasis remain a field of great interest for researchers. Endothelial cells (EC) are involved in disseminating cancer cells to the metastatic sites. Although many researchers have focused on angiogenesis and EC interactions at the primary tumor site, the interplay between cancer cells and ECs at the pre-metastatic niche remains elusive.
Prof. Max Mazzone, VIB-KU Leuven Center for Cancer Biology: “What we knew so far was that a protein called TRAIL, which is part of the armamentarium of our immune system, can limit tumor initiation and metastasis. So far, however, no one has been able to leverage the TRAIL family of proteins in the fight against cancer. It was unknown how TRAIL impacted the tumor microenvironment during metastasis. That’s what we tried to find out.”
On the TRAIL of metastasis
TRAIL – tumor necrosis factor-related apoptosis-inducing ligand – turned out to be more interesting than anticipated. The team discovered that tampering with endothelial TRAIL compromised the integrity of the vascular barrier, promoting inflammatory cell recruitment, and favoring metastatic cell lodging.
Carla Riera Domingo, first author of the study, VIB-KU Leuven Center for Cancer Biology: “To our surprise, we found that adult quiescent endothelial cells expressed unexpectedly high levels of TRAIL and its receptor DR5, allowing them to interact with each other inside the cell. We demonstrated that such interaction is required to block instead of activate DR5 signaling, thereby safeguarding EC survival, reducing EC stickiness, and ultimately ensuring a tight and quiescent barrier. When TRAIL is absent, however, DR5 signaling is unleashed, compromising the integrity of the vascular barrier and ultimately enabling metastasis.”
The team also unraveled two possible mechanisms that could counter the protective function of endothelial TRAIL in the context of cancer dissemination. They found that tumor-derived signals can silence TRAIL, and decoy receptors DcR1 and DcR2 can entrap and inhibit it. This is an important finding as it details how tumors contribute to overruling the protective function of TRAIL and enabling metastasis.
TRAILS of new therapy strategies
Having discovered how TRAIL, or rather the absence of TRAIL, plays an essential role in the dissemination of cancer cells through the vascular barrier, the team set out to find strategies to bypass this mechanism and avoid metastasis. In a preclinical murine model, the team showed that blocking TRAIL receptors or promoting exogenous expression of TRAIL via mRNA delivery by endothelium-targeting lipid nanoparticles can protect against metastasis.
Carla Riera Domingo: “Our experiments confirmed our hypothesis that promoting TRAIL expression in the endothelium could reinforce the vascular barrier and block metastasis. A significant discovery, because it not only furthers our understanding of what enables metastasis in cancer patients, but also prompts the exploration of new strategies to counter the process. In the future, this can lead to better treatment options for cancer patients.”
This research was funded by FWO, ERC, and the VIBTechWatch team.
Publication
Breast tumors interfere with endothelial TRAIL at the pre-metastatic niche to promote cancer cell seeding. Riera-Domingo et al. Science Advances, 2023.
Questions from patients
A breakthrough in research is not the same as a breakthrough in medicine. The realizations of VIB researchers can form the basis of new therapies, but the development path still takes years. This can raise a lot of questions. That is why we ask you to please refer questions in your report or article to the email address that VIB makes available for this purpose: patienteninfo@vib.be. Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address.
About the VIB-KU Leuven Center for Cancer Biology
Cancer has many causes. Often it is a combination of lifestyle, environmental factors, and genetic variation. We need to fight cancer on many fronts, and this can only be done by using knowledge. The VIB-KU Leuven Center for Cancer Biology researchers unravel new mechanisms in order to develop both specific diagnostic methods and treatments.
About VIB
VIB’s core mission is to generate disruptive insights in the molecular underpinning of life and to translate these actively into impactful innovations for patients and society. VIB is an independent research institute where some 1,800 top scientists from Belgium and abroad conduct pioneering basic research. As such, they are pushing the boundaries of what we know about molecular mechanisms and how they rule living organisms such as human beings, animals, plants, and microorganisms. Based on a close partnership with five Flemish universities – Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel, and Hasselt University – and supported by a solid funding program, VIB unites the expertise of all its collaborators and research groups in a single institute. VIB’s technology transfer activities translate research results into concrete benefits for society such as new diagnostics and therapies and agricultural innovations. These applications are often developed by young start-ups from VIB or through collaborations with other companies. This also leads to additional employment and bridges the gap between scientific research and entrepreneurship. VIB also engages actively in the public debate on biotechnology by developing and disseminating a wide range of science-based information.
More info can be found on www.vib.be.
